Defining the Biology of Estrogen Receptor-Low-Positive Breast Cancer.
Tessa Higgins, Olga Kantor, Beth Harrison...
https://pubmed.ncbi.nlm.nih.gov/38161200/Actively Recruiting
Led by Medical University of South Carolina · Updated on 2026-10-15
55
Participants Needed
2
Research Sites
244 weeks
Total Duration
Researchers are evaluating a new treatment approach for people with early-stage triple negative breast cancer TNBC whose tumors have a high level of immune cells called tumor-infiltrating lymphocytes TILs. This study aims to personalize treatment by using a regimen without anthracyclines, which are effective but carry risks, to see if patients with high TIL counts can avoid more toxic therapies while maintaining treatment effectiveness. The trial is a phase II non-inferiority study assessing whether this anthracycline-free approach is not significantly less effective than the current standard treatment. Participants will receive 12 weeks of chemotherapy with carboplatin and paclitaxel combined with the immunotherapy drug pembrolizumab before surgery, omitting anthracyclines during this neoadjuvant phase. After surgery, treatment depends on the pathologic response patients with no remaining cancer continue pembrolizumab alone, while those with residual cancer receive additional anthracycline-based chemotherapy plus pembrolizumab. Some patients may also receive other therapies like olaparib or capecitabine based on their doctors decision. Throughout the study, participants will undergo imaging, lab tests, and physical exams to monitor their condition and treatment response. Researchers will measure the rate of complete cancer response at surgery, event-free survival, overall survival, treatment side effects, and quality of life over several years. Patient-reported outcomes and biological markers will also be collected to better understand treatment effects. Participants will be followed for at least five years after treatment to assess long-term outcomes.
CONDITIONS
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
H
HCC Clinical Trials Office
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Medical University of South Carolina
Lead Sponsor
State University of New York - Upstate Medical University
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational anthracycline‑free regimen | Standard anthracycline‑containing regimen |
|---|---|---|
| What it is | A single‑group neoadjuvant regimen using carboplatin, paclitaxel, and pembrolizumab without anthracyclines in patients with early‑stage TNBC with high TILs | Neoadjuvant chemo‑immunotherapy including anthracycline‑based chemotherapy plus pembrolizumab in high‑risk early‑stage TNBC |
| Role in trial | Investigational treatment being evaluated for de‑escalation of anthracycline use | Represents the current clinical benchmark regimen for context |
| Primary use | Neoadjuvant treatment to achieve pathologic complete response prior to surgery | Neoadjuvant chemo‑immunotherapy to increase pCR and improve long‑term survival |
| How it is given or performed | Carboplatin and paclitaxel administered with pembrolizumab; anthracyclines are omitted | Typically includes pembrolizumab with chemotherapy backbone of taxane‑platinum followed by anthracycline‑based regimen |
| Evidence status | Effectiveness being evaluated; pCR rate and long‑term outcomes unknown | Shown to improve pCR, event‑free survival, and overall survival in KEYNOTE‑522 and meta‑analyses |
| Important risks | Safety profile not yet established; may include immune‑related and chemotherapy‑related toxicities | Known to have immune‑related toxicities and chemotherapy‑associated risks based on KEYNOTE‑522 long‑term data |
| Important limitations | No control arm; outcomes must be interpreted without randomized comparison | Requires anthracycline chemotherapy, which is linked to long‑term cardiotoxicity risk |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility, including review of tumor immune cell levels and overall health assessments.
1 visit (in-person)
Duration - 12 weeks
Participants receive 12 weeks of chemotherapy with carboplatin and paclitaxel plus pembrolizumab before surgery, without anthracycline chemotherapy.
Weekly visits for treatment and monitoring
Duration - Up to 4 weeks
Participants undergo surgery to remove the tumor and lymph nodes. Pathologic response is assessed to guide further treatment.
1 visit for surgery and follow-up assessments
Duration - Variable, depending on response
Participants with no residual cancer continue pembrolizumab alone to complete nine doses. Those with residual disease receive anthracycline-based chemotherapy plus pembrolizumab, with possible additional therapies as recommended by their doctor.
Regular visits for treatment and monitoring
Duration - 5 years
Participants are followed for at least five years to monitor event-free and overall survival, side effects, and quality of life.
Periodic visits for assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Tessa Higgins, Olga Kantor, Beth Harrison...
https://pubmed.ncbi.nlm.nih.gov/38161200/Peter Schmid, Javier Cortes, Rebecca Dent...
https://pubmed.ncbi.nlm.nih.gov/39282906/Nicholas Zdenkowski, Marion J J Kuper-Hommel, Samuel M Niman...
https://pubmed.ncbi.nlm.nih.gov/40049198/Yoonjeong Choi, Seong A Kim, Hanul Jung...
https://pubmed.ncbi.nlm.nih.gov/39009452/Joseph A Sparano, Molin Wang, Silvana Martino...
https://pubmed.ncbi.nlm.nih.gov/18420499/Carlos W Wanderley, David F Colón, João Paulo M Luiz...
https://pubmed.ncbi.nlm.nih.gov/30104241/Steven Lohard, Nathalie Bourgeois, Laurent Maillet...
https://pubmed.ncbi.nlm.nih.gov/31937780/C A Byrd-Leifer, E F Block, K Takeda...
https://pubmed.ncbi.nlm.nih.gov/11500829/Rachel Yoder, Bruce F Kimler, Joshua M Staley...
https://pubmed.ncbi.nlm.nih.gov/35817765/Xiang Huang, Guichun Huang, Haizhu Song...
https://pubmed.ncbi.nlm.nih.gov/20878978/Medical University of South Carolina
Lead Sponsor
State University of New York - Upstate Medical University
Collaborating Sponsor